<DOC>
	<DOCNO>NCT00884676</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , ixabepilone , work different way stop growth tumor cell , either kill cell stop dividing . Sunitinib malate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This phase I trial study side effect best dose ixabepilone give together sunitinib malate treat patient progressive advance solid tumor .</brief_summary>
	<brief_title>Ixabepilone Sunitinib Malate Treating Patients With Progressive Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine safety toxicity profile ixabepilone combination sunitinib malate patient progressive , advanced non-hematologic malignancy . - To determine recommended phase II dose ixabepilone give weekly versus every three week combination fix dose sunitinib malate patient . Secondary - To evaluate pharmacokinetic profile combination ixabepilone sunitinib malate correlate activity and/or toxicity . - To obtain preliminary efficacy data ( complete response , partial response , stable disease ) treatment combination . - To correlate change angiogenesis biomarkers clinical ( safety efficacy ) pharmacokinetic parameter patient treated drug combination . - To estimate optimal biological dose . OUTLINE : This dose escalation study ixabepilone . Patients assign 1 2 treatment group . - Schedule A : Patients receive ixabepilone IV day 1 , 8 , 15 . Beginning day 8 course 1 , patient also receive oral sunitinib malate daily . Courses repeat every 28 day absence disease progression unacceptable toxicity . - Schedule B : Patients receive ixabepilone IV day 1 . Beginning day 8 course 1 , patient also receive oral sunitinib malate daily . Courses repeat every 21 day absence disease progression unacceptable toxicity . Blood sample collect periodically biomarker pharmacokinetic study flow cytometry . After completion study therapy , patient follow 30 day every 3 month 1 year .</detailed_description>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>INCLUSION CRITERIA : Nonhematological malignancy progress standard therapy . Age &gt; 18 . ECOG Performance Status ( PS ) 0 , 1 , 2 . Life expectancy &gt; 3 month . More three prior systemic therapy regimen ( period 4 week chemotherapy immunotherapy ( `` washout period '' ) , must elapse ; 2 week prior tyrosine kinase inhibitor ) . Prior treatment sunitinib 4 week on/2weeks schedule acceptable . Women Child Bearing Potential ( WOCBP ) must use adequate method contraception throughout 4 week study . Patients must either measurable disease ( defined Section 9.0 ) evaluable disease ( bony lesion , pleural effusion , ascites ) Required laboratory value obtain &lt; = 7 day prior registration : Granulocytes ( ANC ) &gt; = 1500/mm3 PLT &gt; = 100,000/mm3 Hgb &gt; = 9.0 g/dL Direct bilirubin &lt; = 1.0 x ULN Alkaline phosphatase &lt; = 2.5 x ULN ( &lt; = 5 x liver metastasis present ) AST/ALT &lt; = 2.5 x ULN ( &lt; = 5 x liver metastasis present ) Creatinine &lt; 1.5 x ULN Pregnancy Test Negative ( For WOCBP* ) Urinalysis Urine protein/creatinine ratio &lt; 1 , &lt; 1+ protein** TSH = WNL INR &lt; = 1.5 , unless patient full dose warfarin stable dose LMW heparin therapeutic INR &gt; 1.5 , &lt; = 3 . Urine protein screen random urine protein : creatinine ratio . For urine protein : creatinine ratio &gt; 1.0 , 24hour urine protein obtain level &lt; 1000 mg patient enrollment . Capable understanding investigational nature , potential risk benefit study able provide valid inform consent . Willingness donate blood correlative marker study . If patient fulldose anticoagulant , follow criterion meet enrollment : The subject must inrange INR ( usually 2 3 ) stable dose warfarin stable dose LMW heparin . No active bleed pathological condition carry high risk bleeding ( e.g . tumor involve major vessel , know varix ) . EXCLUSION CRITERIA : Patients symptomatic/untreated CNS metastasis . Patients know CNS metastasis enrol : CNS metastases appropriately treat . Treatment brain metastasis may include whole brain radiotherapy ( WBRT ) , radiosurgery ( RS ; Gamma Knife , LINAC , equivalent ) resection deem appropriate treating physician . Patients surgical resection CNS metastases brain biopsy within 3 month prior Day 1 exclude . No ongoing requirement dexamethasone , ascertain clinical examination brain imaging ( MRI CT ) screen period . No evidence progression hemorrhage treatment ( brain imaging study within 4 week treatment start ) . CTC Grade 2 great neuropathy ( motor sensory ) study entry . Inability swallow capsule . History gastrointestinal disease , malabsorption , require use feed tube . Patients receive investigational compound within past 28 day ( within 2 week prior RTKI treat patient ) . Patients receive radiotherapy cause le 4 week prior study entry . Patients take cytochrome P450 ( CYP ) 3A4 enzymeinducing enzymeinhibitor medication like : antiepileptic drug ( phenytoin , carbamazepine phenobarbital ) , St John 's Wort , ketoconazole , dexamethasone , dysrhythmic drug ( terfenadine , quinidine , procainamide , sotalol , probucolol , bepridil , indapamide , flecainide ) , haloperidol , risperidone , rifampin , grapefruit ( juice ) within two week registration course therapy . Topical inhale steroid permit . Please refer Appendix VI complete list CYP34A inducer inhibitor . Patients know HIV infection exclude due possibility unknown side effect immune system agent . The potential impact pharmacokinetic interaction antiretroviral therapy ixabepilone sunitinib unknown . Appropriate study may undertake patient HIV receive combination antiretroviral therapy future . Invasive procedure define follow : Major surgical procedure , open biopsy significant traumatic injury &lt; = 28 day prior registration . Anticipation need major surgical procedure course study . Core biopsy &lt; = 7 day prior registration . Port placement &lt; = 7 day prior registration . Serious nonhealing wound , ulcer bone fracture . History abdominal fistula , gastrointestinal perforation intraabdominal abscess &lt; = 28 day . Evidence bleed diathesis coagulopathy . Ongoing hemoptysis , cerebrovascular accident &lt; = previous 6 month , peripheral vascular disease claudication &lt; 1 block , history clinically significant bleeding . Significant cardiovascular disease define congestive heart failure ( New York Heart Association Class II , III IV ) , angina pectoris require nitrate therapy , recent myocardial infarction ( &lt; = last 6 month ) . Patients must absolute baseline leave ventricular ejection fraction ( LVEF ) &gt; = 50 % MUGA scan within 4 week prior registration Uncontrolled hypertension ( define blood pressure &gt; 150 mmHg systolic and/or &gt; 90 mmHg diastolic medication ) . A currently active second malignancy nonmelanoma skin cancer . Patients consider currently active malignancy complete anticancer therapy consider physician less 30 % risk relapse . Any following , regimen may harmful develop fetus nursing child : Pregnant woman Breastfeeding woman Men woman childbearing potential sexual partner unwilling employ adequate contraception ( diaphragm , birth control pill , injection , intrauterine device [ IUD ] , surgical sterilization , subcutaneous implant , abstinence , etc . ) NOTE : The effect agent ( ) develop human fetus recommend therapeutic dose unknown . Other uncontrolled serious medical psychiatric condition ( e.g . cardiac arrhythmia , diabetes , etc . ) Patients must ongoing ventricular cardiac dysrhythmias NCI CTCAE Version 3.0 grade &gt; = 2 . Patients history serious ventricular arrhythmia ( VT VF &gt; = 3 beat row ) also exclude . Additionally , patient ongoing atrial fibrillation eligible . Patients must QTc interval &lt; 500 msec baseline EKG . Prior treatment ixabepilone . History chronic recurrent infection require continuous use antiviral , antifungal antibacterial therapy ; foreseeable need receive antiinfective therapy within 14 day Cycle 1 Day 1 treatment . History Grade 3/4 hypersensitivity reaction Cremophor EL derivative ( polyoxyethylated castor oil ) . Nonsmall cell lung cancer ( NSCLC ) squamous cell type , NSCLC histology involve major blood vessel ( e.g . aorta , pulmonary artery , etc )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>